|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,590,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$31.99 - $31.99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Veitinger Klaus R Dr |
Director |
|
2014-10-10 |
4 |
OE |
$4.65 |
$11,625 |
D/D |
2,500 |
5,212 |
|
- |
|
Berman Lance |
Chief Medical Officer and SVP |
|
2014-09-24 |
4 |
AS |
$22.00 |
$110,000 |
D/D |
(5,000) |
7,500 |
|
- |
|
Berman Lance |
Chief Medical Officer and SVP |
|
2014-09-24 |
4 |
OE |
$3.96 |
$22,033 |
D/D |
5,000 |
12,500 |
|
- |
|
Isaly Samuel D |
10% Owner |
|
2014-09-17 |
4 |
S |
$25.07 |
$1,228,430 |
I/I |
(49,000) |
8,857,551 |
|
- |
|
Isaly Samuel D |
10% Owner |
|
2014-09-16 |
4 |
S |
$25.45 |
$1,146,836 |
I/I |
(45,000) |
8,906,551 |
|
- |
|
5am Co-Investors Ii Lp |
10% Owner |
|
2014-09-16 |
4 |
S |
$26.03 |
$15,944,416 |
I/I |
(612,540) |
50,082 |
|
- |
|
Veitinger Klaus R Dr |
Director |
|
2014-09-10 |
4 |
AS |
$23.00 |
$95,851 |
D/D |
(4,167) |
2,712 |
|
- |
|
Veitinger Klaus R Dr |
Director |
|
2014-09-10 |
4 |
OE |
$4.65 |
$19,377 |
D/D |
4,167 |
6,879 |
|
- |
|
Stahl Wilhelm |
SVP, Pharmaceutical Operations |
|
2014-08-29 |
4 |
AS |
$25.29 |
$399,253 |
D/D |
(15,785) |
5,500 |
|
- |
|
Stahl Wilhelm |
SVP, Pharmaceutical Operations |
|
2014-08-29 |
4 |
OE |
$3.96 |
$66,520 |
D/D |
15,785 |
21,285 |
|
- |
|
5am Co-Investors Ii Lp |
10% Owner |
|
2014-08-26 |
4 |
S |
$26.53 |
$2,555,104 |
I/I |
(96,310) |
73,334 |
|
- |
|
5am Co-Investors Ii Lp |
10% Owner |
|
2014-08-25 |
4 |
S |
$26.50 |
$8,922,285 |
I/I |
(336,690) |
76,990 |
|
- |
|
Berman Lance |
Chief Medical Officer and SVP |
|
2014-08-25 |
4 |
AS |
$26.48 |
$132,379 |
D/D |
(5,000) |
7,500 |
|
- |
|
Berman Lance |
Chief Medical Officer and SVP |
|
2014-08-25 |
4 |
OE |
$7.40 |
$37,000 |
D/D |
5,000 |
12,500 |
|
- |
|
Berman Lance |
Chief Medical Officer and SVP |
|
2014-08-22 |
4 |
AS |
$25.69 |
$385,343 |
D/D |
(15,000) |
7,500 |
|
- |
|
Berman Lance |
Chief Medical Officer and SVP |
|
2014-08-22 |
4 |
OE |
$3.96 |
$65,568 |
D/D |
15,000 |
22,500 |
|
- |
|
Isaly Samuel D |
10% Owner |
|
2014-08-15 |
4 |
S |
$26.35 |
$26,086,500 |
I/I |
(990,000) |
8,951,551 |
|
- |
|
Lockey Claire |
See Remarks |
|
2014-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
5,500 |
|
- |
|
Berman Lance |
Chief Medical Officer and SVP |
|
2014-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
Krasnow Ronald A. |
See Remarks |
|
2014-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
25,848 |
|
- |
|
Ball Kristine M |
Chief Financial Officer & SVP |
|
2014-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
|
- |
|
Corbett Mary |
SVP, Human Resources |
|
2014-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
5,500 |
|
- |
|
Stahl Wilhelm |
SVP, Pharmaceutical Operations |
|
2014-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
5,500 |
|
- |
|
Orwin John A |
President & CEO |
|
2014-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
35,000 |
|
- |
|
Veitinger Klaus R Dr |
Director |
|
2014-08-11 |
4 |
AS |
$27.73 |
$115,563 |
D/D |
(4,167) |
2,712 |
|
- |
|
243 Records found
|
|
Page 9 of 10 |
|
|